FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Nicholas Barbet

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Procedures

Infusions, Intravenous

Co-author Network

Publications

TOP 3
Lillian L Siu; Eric K Rowinsky; Lisa A Hammond; Geoffrey R Weiss; Manuel Hidalgo; Gary M Clark; Judy Moczygemba; Les Choi; Ron Linnartz; Nicholas C Barbet; Ivo Sklenar; Renaud Capdeville; Gregory Gan; Carl W Porter; Daniel Von Hoff; S Gail Eckhardt
A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
Robert Paridaens; D R Uges; Nicholas C Barbet; Les Choi; M Seeghers; W T van der Graaf; H J Groen; Herlinde Dumez; I V Buuren; F Muskiet; Renaud Capdeville; A T Oosterom; E G de Vries
A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours.
Ferry A L M Eskens; GA Greim; C van Zuylen; I Wolff; LJ Denis; A S T Planting; F A Muskiet; Jantien Wanders; Nicholas C Barbet; Les Choi; Renaud Capdeville; Jaap Verweij; Axel R Hanauske; U Bruntsch
Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Nicholas Barbet (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2002: Lillian L Siu; Eric K Rowinsky; Lisa A Hammond; Geoffrey R Weiss; Manuel Hidalgo; Gary M Clark; Judy Moczygemba; Les Choi; Ron Linnartz; Nicholas C Barbet; Ivo Sklenar; Renaud Capdeville; Gregory Gan; Carl W Porter; Daniel Von Hoff; S Gail Eckhardt
A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2157-66.
2000: Robert Paridaens; D R Uges; Nicholas C Barbet; Les Choi; M Seeghers; W T van der Graaf; H J Groen; Herlinde Dumez; I V Buuren; F Muskiet; Renaud Capdeville; A T Oosterom; E G de Vries
A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours.
British journal of cancer 2000;83(5):594-601.
2000: Ferry A L M Eskens; GA Greim; C van Zuylen; I Wolff; LJ Denis; A S T Planting; F A Muskiet; Jantien Wanders; Nicholas C Barbet; Les Choi; Renaud Capdeville; Jaap Verweij; Axel R Hanauske; U Bruntsch
Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(5):1736-43.
2000: H Zhou; Les Choi; H Lau; U Bruntsch; E E Vries; G Eckhardt; A T Oosterom; Jaap Verweij; Horst Schran; Nicholas C Barbet; R Linnartz; Renaud Capdeville
Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancers.
Journal of clinical pharmacology 2000;40(3):275-83.